Unity Biotechnology, Inc. (UBX)
- GlobeNewswire
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2023. "On the heels of positive BEHOLD data, our team is currently single-mindedly focused on the enrollment and execution of our Phase 2b ASPIRE study in diabetic macular edema, comparing UBX1325 (foseluto
- GlobeNewswire
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal Nature Medicine that supports the clearance of senescent cells in the retina as a therapeutic approach that can lead to long-term improvements in vision in patients with diabetic macular edema (DME). Sustained hyperglycemia fr
- Insider Monkey
10 Supplements for Longevity and Antiaging: Expert Recommendations
In this article, we are going to discuss the 10 Supplements for Longevity and Antiaging: Expert Recommendations. You can skip our detailed analysis and go directly to 5 Supplements for Longevity and Antiaging: Expert Recommendations. The anti-aging and longevity market is undergoing a fascinating transformation, driven by personalized approaches, cutting-edge science, and a growing emphasis on evidence-based […]
